Nitrofurantoin for UTI: Dosing, and Why It Fails Above the Bladder

Nitrofurantoin is unusual among antibiotics because its greatest strength and its most dangerous limitation are the same property. It concentrates in urine and barely reaches anything else. That makes it excellent for a bladder infection and useless for a kidney infection, and the label says so directly: it is not indicated for pyelonephritis or perinephric abscess. Someone treating flank pain and fever with nitrofurantoin is taking a drug that cannot reach the infection. This guide covers labelled dosing and the boundaries that matter.

Why it only works in the bladder

The label states plainly that nitrofurantoins lack the broader tissue distribution of other agents approved for urinary tract infections. The drug is absorbed, rapidly cleared into the urine, and concentrated there. Blood and tissue concentrations stay low.

For an infection confined to bladder urine, that is close to ideal. Drug goes where the bacteria are, and the rest of the body sees very little, which is why nitrofurantoin drives less collateral resistance than broad spectrum alternatives and why it has held up as a first line agent for uncomplicated cystitis for decades while resistance to other agents climbed.

For an infection in kidney tissue, the same property is disqualifying. Pyelonephritis is a tissue infection, and nitrofurantoin does not achieve useful tissue levels. Fever, flank or back pain, nausea, vomiting or feeling systemically unwell suggests the infection has moved above the bladder and needs a different antibiotic and urgent assessment.

Labelled dosing for adults

The recommended adult dose is 50 mg to 100 mg four times a day, with the lower end recommended for uncomplicated urinary tract infections.

Use	Dose
Uncomplicated urinary tract infection	50 mg four times daily
Standard treatment range	50 mg to 100 mg four times daily
Long term suppressive therapy	50 mg to 100 mg at bedtime

Treatment continues for one week, or for at least three days after the urine is sterile. Infection that persists past that indicates the need for reassessment rather than a longer course of the same drug. Stock includes Niftas 50mg, Martifur 100mg, Martifur MR 50mg and Martifur MR 100mg.

Modified release preparations exist to reduce dosing frequency and improve gastrointestinal tolerance, and are typically taken twice daily rather than four times. Immediate release and modified release forms are not interchangeable tablet for tablet, so the frequency should follow the specific product dispensed.

Always take it with food

The label directs administration with food to improve absorption, and notes it improves tolerance in some patients. This is not a minor point. Nitrofurantoin absorption is meaningfully increased by food, so a dose taken on an empty stomach delivers less drug to the urine.

Since nausea is among the most common reasons people abandon a course, and food addresses both the absorption and the nausea, taking every dose with a meal or substantial snack is the single most useful practical habit with this drug.

Dosing in children

For children aged one month and older, the dose is 5 mg/kg to 7 mg/kg of body weight per 24 hours, given in four divided doses. Nitrofurantoin is contraindicated under one month of age.

The neonatal contraindication exists because the enzyme systems that protect red blood cells are immature in very young infants, creating a risk of haemolytic anaemia. For long term suppressive therapy in children, doses as low as 1 mg/kg per 24 hours have been used. Paediatric dosing needs a weight based calculation and a properly graduated oral syringe rather than a kitchen spoon.

The pulmonary reaction nobody expects

This is the warning that most distinguishes nitrofurantoin from other UTI antibiotics, and the one most often missed. Acute, subacute and chronic pulmonary reactions have all been reported, and the label states that pulmonary reactions have been cited as a contributing cause of death.

Acute reactions usually appear within the first week and present with fever, chills, cough, chest pain, breathlessness and changes on chest imaging, along with eosinophilia. They are generally reversible when the drug is stopped.

Chronic reactions are the more serious problem. They occur generally in patients on continuous treatment for six months or longer, which in practice means people on long term suppressive therapy for recurrent infections. Onset is insidious: malaise, breathlessness on exertion, cough and declining lung function, with diffuse interstitial pneumonitis or fibrosis on imaging. Lung function can be permanently impaired even after the drug is stopped, and the severity relates directly to how long treatment continued after the first symptoms appeared.

The practical implication is that anyone on long term nitrofurantoin who develops a gradually worsening cough or breathlessness should have the drug considered as the cause rather than being investigated for a chest infection and given more antibiotics.

The other serious warnings

Peripheral neuropathy has occurred and may become severe or irreversible, with fatalities reported. Risk is higher in renal impairment, anaemia, diabetes, electrolyte imbalance, vitamin B deficiency and debilitating disease. Numbness, tingling or burning in the hands or feet during treatment needs prompt review.

Hepatic reactions including hepatitis, cholestatic jaundice, chronic active hepatitis and hepatic necrosis have occurred, with fatalities reported. The onset of chronic active hepatitis can be insidious, so periodic liver monitoring is advised on long term therapy.

Haemolytic anaemia can occur, particularly in people with glucose 6 phosphate dehydrogenase deficiency, which is common in parts of Africa, the Mediterranean, the Middle East and South and Southeast Asia. Serious and occasionally fatal anaphylactic reactions have been reported. Clostridioides difficile associated diarrhoea can follow treatment.

Kidney function is the deciding factor

Nitrofurantoin depends on adequate kidney function to reach therapeutic concentrations in urine. As renal function declines, less drug reaches the bladder while more accumulates systemically. That combination is the worst of both outcomes: falling efficacy alongside rising toxicity risk, particularly neuropathy.

This is why nitrofurantoin is avoided in significant renal impairment, and why the threshold has been the subject of ongoing revision by regulators. The specific cutoff should come from a prescriber who has your measured kidney function, not from a general figure. Anyone with known kidney disease, and most older adults, needs that checked before a course.

Pregnancy and the term exception

Nitrofurantoin is used in pregnancy for urinary infections, which are both common and consequential in pregnancy, but it is avoided at term. The concern is haemolytic anaemia in the newborn, whose immature red cell enzyme systems mirror the reason it is contraindicated in infants under one month.

Use during pregnancy is a decision for the treating clinician weighing the specific stage and the alternatives. Untreated bacteriuria in pregnancy carries real risks of its own, so this is a balance rather than a blanket avoidance.

Why it stays effective when other options do not

Resistance to nitrofurantoin among Escherichia coli, which causes the large majority of uncomplicated urinary infections, has remained low in most regions despite decades of use. Two features explain that. It has multiple mechanisms of antibacterial action rather than a single target, which makes single step resistance mutations less likely. And its confinement to urine means it exerts little selection pressure on bacteria elsewhere in the body.

That combination is why guidelines in many countries place it first line for uncomplicated cystitis ahead of fluoroquinolones and cephalosporins, and why it is worth protecting. Using it where it is indicated, and not using it for infections it cannot reach, is what keeps it working.

How it compares with the other cystitis options

Nitrofurantoin is one of several agents used for uncomplicated bladder infection, and each trades off differently.

Agent	Typical course	Reaches kidney tissue	Main drawback
Nitrofurantoin	5 to 7 days	No	Useless above the bladder, needs adequate renal function
Trimethoprim	3 days	Yes	Rising resistance in many regions
Cephalexin	5 to 7 days	Yes	Broader spectrum, more collateral resistance
Fluoroquinolones	3 days	Yes	Boxed warnings, reserved rather than first line

Guidance in most countries now steers away from fluoroquinolones such as Norflox 400mg for simple cystitis because of tendon, nerve and aortic warnings, keeping them for infections where nothing narrower works. Cephalexin, available as Phexin 500mg and Cephadex 500mg, does reach kidney tissue and so remains an option when the infection may have ascended. Which agent fits depends on the organism, local resistance patterns and kidney function, which is a prescribing decision rather than a shopping one.

Brown urine and other harmless effects

Nitrofurantoin commonly turns urine dark yellow, brown or rust coloured. This is the drug and its metabolites being excreted, it is expected, and it is not blood or a sign of liver or kidney damage. It resolves within a day or two of finishing the course.

Distinguishing this from genuine blood in the urine matters. Drug discolouration is uniform, develops soon after starting and affects every void. Frank blood tends to be red or pink rather than brown, may be intermittent, and often comes with worsening rather than improving symptoms. Blood in the urine warrants assessment rather than being attributed to the tablet.

Headache, mild nausea and loss of appetite are also common and usually settle. Taking each dose with food addresses most of the gastrointestinal complaints, which is one more reason the food instruction is worth following.

What needs assessment rather than a tablet

Not every episode of urinary discomfort is a bacterial infection, and not every bacterial infection is confined to the bladder. Several situations need clinical assessment rather than empirical treatment: fever or flank pain, blood in the urine, symptoms in men, symptoms in pregnancy, symptoms in anyone with a catheter or a known urinary tract abnormality, recurrent infections, and any episode that fails to respond within a few days.

Urine culture and susceptibility testing before and after treatment is what the label recommends, and it matters more with nitrofurantoin than with broader agents because the drug covers a narrower range of organisms. Proteus and most Pseudomonas species, for example, are typically not susceptible. Persistence or reappearance of bacteria after a course indicates that an agent with broader tissue distribution should be selected.

Safety information

Nitrofurantoin is a prescription only medicine in the United States, United Kingdom, Australia and Canada. It treats bladder infections and does not treat kidney infections. Take every dose with food. Seek urgent medical attention for fever, flank or back pain, breathlessness, a persistent cough, yellowing of the skin or eyes, or numbness and tingling in the hands or feet. Tell your prescriber if you have kidney disease, G6PD deficiency, diabetes, anaemia or nerve problems, or if you are pregnant or breastfeeding. Speak to a licensed clinician before starting or changing this medicine. For a broader spectrum option, see our amoxicillin and clavulanate dosage guide.

References

• FDA prescribing information, nitrofurantoin: sections 2.1 to 2.3 dosage and administration, 5.1 to 5.7 warnings and precautions, and 6 adverse reactions
• DailyMed label, nitrofurantoin capsules (macrocrystals): indications and usage section, including the statement that it is not indicated for pyelonephritis or perinephric abscesses
• Nitrofurantoin oral suspension paediatric dosing table by body weight, section 2.2 of the label